Swiss drugmaker Roche has entered a partnership with Atavistik Bio potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases. The deal includes $70 million upfront with an additional $1.9 billion in potential milestone payments.
Insilico Medicine announced that rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reduce biological age markers in a 42-patient trial. Six independently built aging clocks all showed patients on the drug appeared biologically younger, according to a study conducted with researchers from Harvard Medical School, Stanford University, and The Broad Institute.
Rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reverse biological signs of aging in a study, according to its developer, suggesting broader potential applications beyond its original target condition.
Michael Polansky's biotech startup Outer Biosciences has emerged from stealth after four years, revealing technology that keeps surgically discarded human skin tissue alive for up to a month outside the body. The company trains AI models on how the living tissue reacts to compounds to discover new skincare treatments.
Researchers at the University of Utah Health have used artificial intelligence and genetic analysis to identify molecular signals and drug candidates that could modify osteoarthritis disease progression, moving beyond current symptom-management approaches. The research includes insights into purinergic signaling pathways that influence joint inflammation and cartilage degeneration.
